40OBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). (25th November 2018) - Yap, Y S; Masuda, N; Ito, Y; Ishikawa, T; Kim, S J; Aruga, T; Toyama, T; Saeki, T; Yamanaka, T; Saito, M; Watanabe, J; Takahashi, M; et al.